Fig. 2
From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Peak FEV1 between 0 and 3 h post-dose (full analysis set). Data are least squares means treatment–placebo differences and 95% confidence intervals. ‡p < 0.001 vs placebo. Least squares mean changes from baseline in the placebo group (N = 79) were 36, 50, 42 and 57 mL at Weeks 1, 2, 3 and 4, respectively. Abbreviation: FEV1, forced expiratory volume in 1 s